Review finds combining angiotensin receptor blockers with ACE inhibitors in heart failure may only benefit people with contraindications to β blockersAbstracted from: Dimopoulos K, Salukhe TV, Coats AJ, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 2004; 93(2–3): 105–11.

2004 ◽  
Vol 8 (3) ◽  
pp. 241-242
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Beta Blocker ◽  
Angiotensin Receptor Blocker ◽  
Ace Inhibitor ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Mortality And Morbidity ◽  
Receptor Blockers ◽  
Meta Analyses

scholarly journals Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice

2005 ◽  
Vol 6 (2_suppl) ◽  
pp. S6-S10 ◽  
Author(s):  
Karl Swedberg
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricular Systolic Dysfunction ◽  
Angiotensin Receptor Blockers ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
High Dose ◽  
Mortality And Morbidity ◽  
European Guidelines ◽  
Receptor Blockers

European guidelines for the management of chronic heart failure (CHF) have been recently updated. Key changes include emphasis on CHF with preserved ejection fraction, and recognition of the role of angiotensin receptor blockers (ARBs) in the management of CHF patients with left ventricular systolic dysfunction who remain symptomatic despite optimal therapy, or who are intolerant to angiotensin-converting enzyme (ACE) inhibitors. Recent trials that clearly demonstrated significant mortality and morbidity benefits were integral to these new recommendations. Additionally, a high dose of an ARB, as demonstrated in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) programme, can significantly reduce hospitalisation for heart failure in these settings. The guidelines recommend that only those ARBs and doses used in clinical trials should be considered, taking into account current licensed indications. Clinicians who are directly involved in the management of CHF must play a key role in the dissemination of these guidelines to colleagues to ensure that optimal CHF management is integrated into standard practice.

Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure

2011 ◽  
Vol 21 (3) ◽  
pp. 233-240 ◽  
Author(s):  
Rishi J. Desai ◽  
Carol M. Ashton ◽  
Anita Deswal ◽  
Robert O. Morgan ◽  
Hemalkumar B. Mehta ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Comparative Effectiveness ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Risk Of Mortality ◽  
Receptor Blockers
Sign in / Sign up

Export Citation Format

Share Document